Cytori Therapeutics to Provide Update on Breast Reconstruction Commercialization Timeline from the 2nd Annual Stem Cell Summit
fwiw...
ir.cytoritx.com
Best of Luck,
SS
>>>
Cytori Therapeutics to Provide Update on Breast Reconstruction Commercialization Timeline from the 2nd Annual Stem Cell Summit
Feb. 8, 2007, San Diego, Calif. – Cytori Therapeutics, Inc., (NASDAQ: CYTX; Frankfurt: XMPA) will outline its commercialization strategy for the Celution™ System breast reconstruction product and provide an update on the start of the Celution™ System cardiovascular disease clinical trial Monday, February 12, at 11:35 AM Eastern Standard Time from the 2nd Annual Stem Cell Summit. The live audio presentation and slides will be made available from a link in the Investor Relations section of Cytori's website at cytoritx.com. A replay will be available on the Company's website approximately one hour following the live presentation.
The Stem Cell Summit
The 2nd Annual Stem Cell Summit, Feb. 12-13, 2007 in San Diego CA, will be the largest gathering of stem cell company executives, scientists, investors and physicians. The meeting will focus on stem cell products that are on the market or expected to enter the market in the very near future. The agenda includes company and product overviews, the latest clinical stem cell developments, and the first live surgery of a stem-cell-based product in the operating room. The conference is being produced by RRY Publications and Robin Young Consulting Group. The full agenda and registration details are at stemcellsummit.com
Cytori Therapeutics
Cytori Therapeutics is developing and seeks to commercialize stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious chronic, and life threatening conditions. To provide these therapies, physicians remove a small amount of a patient's fat, also known as adipose tissue, and run it through Cytori's Celution™ System. This System quickly separates and concentrates stem and regenerative cells from adipose tissue so they may be quickly administered back to the patient about an hour later. This system will dramatically improve the way in which personalized cell-based therapies can be delivered to patients. www.cytoritx.com
Contact:
Investors: Tom Baker; 858-875-5258; tbaker@cytoritx.com
Media: Amy Blackley, Ph.D. (Porter Novelli Life Sciences); 619-849-6008; ablackley@pnlifesciences.com |
